IC
KZR

Ikarian Capital’s Kezar Life Sciences KZR Stock Holding History

Ikarian Capital’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-107,530
Closed -$8.89M – 139
2022
Q2 		$8.89M Buy
107,530
+79,450
+283% +$7.01M 1.62% 20
2022
Q1 		$4.67M Buy
28,080
+11,150
+66% +$1.6M 0.61% 45
2021
Q4 		$2.83M Buy
+16,930
New +$1.91M 0.42% 52

Other funds holding KZR

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Ikarian Capital's KZR Position: Q1 2026 in Review

Ikarian Capital held its Kezar Life Sciences (KZR) position steady in Q1 2026 at 102,211 shares worth $758K. The position accounts for 0.06% of the portfolio, ranked #115.

Ikarian Capital first reported a position in KZR in Q4 2021 and has held it in 18 quarters since. The position peaked at $18M in Q1 2022. 43 funds tracked by Wall St. Rank hold KZR as of Q1 2026.

  • Ikarian Capital held 102,211 shares of Kezar Life Sciences worth $758K as of Q1 2026.
  • Ikarian Capital left its Kezar Life Sciences share count unchanged in Q1 2026.
  • Kezar Life Sciences made up 0.06% of Ikarian Capital's portfolio in Q1 2026, its #115 holding.
  • Ikarian Capital first reported a position in Kezar Life Sciences in Q4 2021 and has held it in 18 quarters since.
  • Ikarian Capital's Kezar Life Sciences position peaked at $18M in Q1 2022.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.